R-Pharm Announced The Registration Of Coronavir And Artlegia Drugs In Azerbaijan

R-Pharm Announced The Registration Of Coronavir And Artlegia Drugs In Azerbaijan
R-Pharm Announced The Registration Of Coronavir And Artlegia Drugs In Azerbaijan

Video: R-Pharm Announced The Registration Of Coronavir And Artlegia Drugs In Azerbaijan

Video: OCCUPIED TERRITORIES OF AZERBAIJAN USED FOR DRUG TRAFFICKING 2022, November
Anonim

The R-Pharm group of companies has completed the registration process in Azerbaijan for two proprietary drugs - Coronavir (favipiravir) and Artlegia (olokizumab), according to a press release received by Gazeta.Ru on December 25. on Friday. Coronavir is used in Russia for the treatment of mild to moderate coronavirus infection and is included in the guidelines of the Ministry of Health of the Russian Federation for the treatment of Covid-19. The original development of R-Pharm, the drug Artlegia (olokizumab), is registered on the territory of the Russian Federation for the main indication "rheumatoid arthritis", and is also recommended by the Ministry of Health of the Russian Federation in the treatment of the moderate form of Covid-19 in order to suppress hyperinflammation and to prevent the development of serious lung lesions and other organs caused by coronavirus infection. "The ability of favipiravir to suppress infection in the early stages of the disease, preventing further development of the disease, has been proven in the framework of a clinical study," says Mikhail Samsonov, medical director of R-Pharm. "The just completed study of olokizumab in real clinical practice has shown its effectiveness in prevention of the development of hyperactivation of the immune response in patients with a moderate course ". "We are glad that a complex of drugs will appear in the arsenal of the Azerbaijani healthcare system that can have a significant effect on the therapy of a number of socially significant diseases at once," Samsonov said.

Popular by topic